Human study · Research · 14 Nov 2026
In 501 men with metastatic prostate cancer, a higher neutrophil-lymphocyte ratio lined up with poorer survival on LuPSMA
Source: Prostate Cancer and Prostatic Diseases
What the research found
A retrospective brief report was published on 14 November 2026. It covered 501 men treated with lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer after a taxane, at two centers, from 2022 to 2024. The public abstract does not give age or a hazard ratio. A neutrophil-lymphocyte ratio above 3 at cycle 1 independently lined up with poorer survival. Men above that line at both cycle 1 and cycle 2 had the poorest outcomes. The abstract does not give the survival times. This is a records analysis of a blood ratio during care, not a trial of the ratio itself. DOI 10.1038/s41391-026-01173-w. Not medical advice.
Evidence level: Human study. A study in people, but an association isn't proof of cause.
More research news
- In 9,156 adults aged 45 and older, a higher triglyceride-glucose index lined up with more chronic liver disease
- Statin-ezetimibe lined up with fewer myocardial infarctions than statin use alone in a Korean records study
- In 7,428 women treated for Hodgkin lymphoma before age 36, later invasive cancers stayed more common than expected
- In 283 very preterm infants, biomarker-guided antibiotics did not show noninferiority for survival without major morbidity
- In 34,731 US service members, higher cumulative stress lined up with more days of health care